The Effectiveness of Different Doses of Iron Supplementation and the Prenatal Determinants of Maternal Iron Status in Pregnant Spanish Women: ECLIPSES Study.
Study Goal
The researchers aimed to evaluate the effectiveness of different iron supplementation doses adjusted for initial hemoglobin levels on maternal iron status and identify associated prenatal determinants.
Results Summary
In women with lower initial hemoglobin (110-130g/L), 80 mg/d iron protected against iron deficiency at week 36, while those with iron deficiency at week 12 saw improved hemoglobin levels. In women with higher initial hemoglobin (>130g/L), 20 mg/d reduced hemoconcentration risk, and 40 mg/d improved ferritin levels in those with early pregnancy iron deficiency.
Population
791 pregnant women stratified by initial hemoglobin levels.
Effective Dosage
20 mg/d, 40 mg/d, or 80 mg/d, depending on hemoglobin stratum.
Duration
Administered until week 36 of pregnancy.
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
80 mg/d iron supplementation | decrease | iron deficiency (ID) | women in Stratum 1 (Hb = 110-130g/L) | - | protected against | #1 |
80 mg/d iron supplementation | decrease | anemia | women with ID on week 12 | - | protected against | #2 |
80 mg/d iron supplementation | decrease | iron deficiency anemia (IDA) | women with ID on week 12 | - | protected against | #3 |
80 mg/d iron supplementation | increase | Hb levels | women with ID on week 12 | - | increased | #4 |
20 mg/d iron supplementation | decrease | hemoconcentration | women in Stratum 2 (Hb > 130g/L) with initial serum ferritin (SF) ≥ 15 μg/L | - | reduced the risk of | #5 |
40 mg/d iron supplementation | increase | SF levels | women in Stratum 2 (Hb > 130g/L) with ID in early pregnancy | - | improved | #6 |
Iron deficiency (ID), anemia, iron deficiency anemia (IDA) and excess iron (hemoconcentration) harm maternal-fetal health. We evaluated the effectiveness of different doses of iron supplementation adjusted for the initial levels of hemoglobin (Hb) on maternal iron status and described some associated prenatal determinants. The ECLIPSES study included 791 women, randomized into two groups: Stratum 1 (Hb = 110-130g/L, received 40 or 80mg iron daily) and Stratum 2 (Hb > 130g/L, received 20 or 40mg iron daily). Clinical, biochemical, and genetic information was collected during pregnancy, as were lifestyle and sociodemographic characteristics. In Stratum 1, using 80 mg/d instead of 40 mg/d protected against ID on week 36. Only women with ID on week 12 benefited from the protection against anemia and IDA by increasing Hb levels. In Stratum 2, using 20 mg/d instead of 40 mg/d reduced the risk of hemoconcentration in women with initial serum ferritin (SF) ≥ 15 μg/L, while 40 mg/d improved SF levels on week 36 in women with ID in early pregnancy. Mutations in the